Home / Cancer treatment in China / Breast cancer treatment / Immunotherapy
Not for every subtype
Breast Cancer Immunotherapy: Who It Is For
Immunotherapy is not a treatment for all breast cancer. The National Cancer Institute’s patient page on treatment by stage says this kind of treatment is used for triple-negative breast cancer. Triple-negative means the cancer is negative for estrogen receptor, progesterone receptor, and HER2. Even inside that group, immunotherapy is not automatic: stage, prior therapy, and whether a PD-1 or PD-L1 drug is appropriate still matter. Other subtypes have different established tools.
Applicability: a HER2-positive or hormone-receptor-positive cancer is not moved onto immunotherapy just because the word appears in an advertisement.
Triple-negativeNot every TNBC caseTrial is not approval
What NCI says
On the treatment-by-stage page, NCI places immunotherapy in one bullet: it is used to treat triple-negative breast cancer. Hormone therapy is the bullet for estrogen and progesterone receptors. HER2-targeted and other targeted drugs are a separate bullet, including BRCA-associated disease. Mixing those bullets is how “immunotherapy for breast cancer” becomes an unsupported claim.
Pembrolizumab is on the NCI list of drugs approved for breast cancer. That listing is not a statement that every person with breast cancer should receive it.
Triple-negative does not mean one drug
On 22 May 2026 the FDA approved datopotamab deruxtecan for adults with unresectable or metastatic triple-negative disease who are not candidates for a PD-1/PD-L1 inhibitor and who had not received chemotherapy for metastatic disease. That approval is an antibody-drug conjugate, not proof that immunotherapy failed as a concept, and not proof that immunotherapy fits the people who are candidates for a PD-1/PD-L1 drug. The two routes are different. Details are on the FDA page and on the approvals page.
Trials and other subtypes
Researchers study immune drugs in other breast-cancer subtypes. A study is not an approval and not a hospital package. This site does not treat a phase 1 result as care someone can book. A trial question needs a registry identifier and a conversation about eligibility. Eligibility is decided by the trial site, not by this page.
When a case review may help
A review can ask whether an offer of “immunotherapy” names the subtype, the drug, and the line of therapy. It should refuse a quote that uses the word for HR-positive or HER2-positive disease without a trial identifier. Records stay in the messaging app, not in analytics.
In this cluster
- Breast cancer treatment
- Treatment by stage
- Latest treatment
- How curable it is
- Immunotherapy (this page)
- Treatment in China
Questions people ask
Is immunotherapy suitable for all breast cancer?
No. NCI’s patient explanation limits immunotherapy to triple-negative disease, and even that group is not one regimen.
Is an antibody-drug conjugate the same as immunotherapy?
No. Trastuzumab deruxtecan and datopotamab deruxtecan are targeted antibody-drug conjugates with their own approvals. They are not a reason to call every new drug immunotherapy.
Can I assume a cancer hospital in China provides pembrolizumab for my case?
No. This page does not verify stock, indication match, or international-patient access. The China routing page is where that limit is stated.
Sources
- NCI, Breast Cancer Treatment by Stage. States that immunotherapy is used to treat triple-negative breast cancer.
- NCI, Drugs Approved for Breast Cancer. Pembrolizumab appears on the breast-cancer drug list.
- FDA, datopotamab deruxtecan for triple-negative disease. 22 May 2026 approval for patients who are not PD-1/PD-L1 inhibitor candidates.
Evidence check: 3 October 2026. US approvals are not proof that a hospital in China stocks the drug or will accept an international patient.
Check whether immunotherapy is the right question
Immunotherapy is not a treatment for every breast cancer subtype. ParkMega does not decide eligibility.